Fol. Biol. 2018, 64, 97-102
https://doi.org/10.14712/fb2018064030097
Serum Levels of Aryl Hydrocarbon Receptor, Cytochromes P450 1A1 and 1B1 in Patients with Exacerbated Psoriasis Vulgaris
References
1. 2010) The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br. J. Dermatol. 163, 928-934.
< , G., Krüger-Krasagakis, S., Krasagakis, K., Fragiadaki, I., Kokolakis, G., Tosca, A. (https://doi.org/10.1111/j.1365-2133.2010.09935.x>
2. 2001) Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J. Invest. Dermatol. 116, 541-548.
< , J. M., Höller, D., Schiffer, R., Frankenberg, S., Neis, M., Merk, H. F., Jugert, F. K. (https://doi.org/10.1046/j.1523-1747.2001.01298.x>
3. 2016) Genetic polymorphisms in biotransformation enzymes for benzo[a] pyrene and related levels of benzo[a]pyrene-7,8-diol-9,10- epoxide-DNA adducts in Goeckerman therapy. Toxicol. Lett. 255, 47-51.
< , M., Fiala, Z., Kremlacek, J., Andrys, C., Hamakova, K., Chmelarova, M., Palicka, V., Borska, L. (https://doi.org/10.1016/j.toxlet.2016.05.009>
4. 2017) Changes in circulating cell-free DNA and nucleosomes in patients with exacerbated psoriasis. Arch. Dermatol. Res. 309, 815-821.
< , M., Fiala, Z., Kremlacek, J., Andrys, C., Krejsek, J., Hamakova, K., Chmelarova, M., Palicka, V., Borska, L. (https://doi.org/10.1007/s00403-017-1785-5>
5. 1998) Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm. Venereol. 78, 22-26.
< , C., Mussi, A., Carducci, M., Pittarello, A., D’Auria, L., Venuti, A., Bagnato, A., Salani, D., Fazio, M., Ameglio, F. (https://doi.org/10.1080/00015559850135779>
6. 2010) Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J. Eur. Acad. Dermatol. Venereol. 24, 1386-1394.
< , S., Oliveira, H., Reis, F., Belo, L., Rocha, S., Quintanilha, A., Figueiredo, A., Teixeira, F., Castro, E., Rocha- Pereira, P., Santos-Silva, A. (https://doi.org/10.1111/j.1468-3083.2010.03647.x>
7. 2014) AHR: making the keratinocytes thick skinned. Immunity 40, 863-864.
< , M. (https://doi.org/10.1016/j.immuni.2014.06.001>
8. 2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43, 309-334.
< , M. S., Nagy S. R. (https://doi.org/10.1146/annurev.pharmtox.43.100901.135828>
9. 2013) Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. J. Dermatolog. Treat. 24, 2-6.
< , M,, Bhutani, T., Koo, J., Liao, W. (https://doi.org/10.3109/09546634.2011.607794>
10. 2010) The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31, 1319-1328.
< , C., Kaina, B. (https://doi.org/10.1093/carcin/bgq028>
11. 2014) Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 40, 989-1001.
< , P., Duarte, J. H., Ahlfors, H., Owens, N. D., Li, Y., Villanova, F., Tosi, I., Hirota, K., Nestle, F. O., Mrowietz, U., Gilchrist, M. J., Stockinger, B. (https://doi.org/10.1016/j.immuni.2014.04.019>
12. 2013) Estimation of tissue osteopontin levels before and after different traditional therapeutic modalities in psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 27, 351-355.
< , N. H., Kadry, D., Hegazy, R. A., Rashed, L. (https://doi.org/10.1111/j.1468-3083.2011.04417.x>
13. 2013) Functions of the aryl hydrocarbon receptor in the skin. Semin. Immunopathol. 35, 677-691.
< , C., Bargen, I., Weighardt, H., Haarmann-Stemmann, T., Krutmann, J. (https://doi.org/10.1007/s00281-013-0394-4>
14. 1991) Benzo[a]pyrene diolepoxide-DNA adducts in alveolar macrophages of smokers. Carcinogenesis 12, 1281-1285.
< , A., Rossi, G. A., Bagnasco, M., De Flora, S. (https://doi.org/10.1093/carcin/12.7.1281>
15. 2011) The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin. Exp. Dermatol. 36, 845-850.
< , A., Liapi, C., Katoulis, A., Stavropoulos, P., Avgerinou, G., Georgala, S., Economopoulos, T., Stavrianeas, N. G., Katsambas, A. (https://doi.org/10.1111/j.1365-2230.2011.04131.x>
16. 2017) An investigation of cytochrome p450 (CYP) and glutathione S-transferase (GST) isoenzyme protein expression and related interactions with phototherapy in patients with psoriasis vulgaris. Int. J. Dermatol. 56, 225-231.
< , A. S., Uzunçakmak, T. K., Ozkanli, S., Oguztuzun, S., Moran, B., Akbulak, O., Ozlu, E., Zemheri, I. E., Bilgili, S. G., Akdeniz, N. (https://doi.org/10.1111/ijd.13343>
17. 2000) Ultraviolet- B exposure of human skin induces cytochromes P450 1A1 and 1B1. J. Invest. Dermatol. 114, 328-333.
< , S. K., Matsui, M. S., Mukhtar, H. (https://doi.org/10.1046/j.1523-1747.2000.00876.x>
18. 2014) Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. Exp. Dermatol. 23, 278-281.
< , H. O., Kim, J. H., Chung, B. Y., Choi, M. G., Park, C. W. (https://doi.org/10.1111/exd.12350>
19. 2017) AhR mediates an anti-inflammatory feedback mechanism in human Langerhans cells involving FcεRI and IDO. Allergy 72, 1686-1693.
< , S., Stroisch, T. J., Vorac, J., Herrmann, N., Leib, N., Schnautz, S., Kirins, H., Förster, I., Weighardt, H., Bieber, T. (https://doi.org/10.1111/all.13170>
20. 2015) Selected inflammatory and metabolic markers in psoriatic patients treated with Goeckerman therapy. Mediators Inflamm. 2015, 979526.
< , K., Borska, L., Andrys, C., Krejsek, J., Hamakova, K., Rendarova, S., Rehacek, V., Kremlacek, J., Fiala, Z. (https://doi.org/10.1155/2015/979526>
21. 2017) Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications. Biochem. Biophys. Res. Commun. 491, 675-680.
< , S., Sinha, N., Gerth, K. A., Rahman, M. A., Yallapu, M. M., Midde, N. M. (https://doi.org/10.1016/j.bbrc.2017.07.145>
22. 2014) Patient perspectives in the management of psoriasis: results from the populationbased Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J. Am. Acad. Dermatol. 70, 871-881.
< , M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., Paul, C. F., Puig, L., Reich, K., van de Kerkhof, P. C. (https://doi.org/10.1016/j.jaad.2013.12.018>
23. 2004) Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J. Invest. Dermatol. 122, 830-836.
< , R. J., Schultz, J. E., Boehncke, W. H., Podda, M., Tandi, C., Krombach, F., Baatz, H., Kaufmann, R., von Andrian, U. H., Zollner, T. M. (https://doi.org/10.1111/j.0022-202X.2004.22318.x>
24. 2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279, 23847-23850.
< , D. W., Dalton, T. P., Okey, A. B., Gonzalez, F. J. (https://doi.org/10.1074/jbc.R400004200>
25. 2018) Up-regulated expression of CD86 on circulating intermediate monocytes correlated with disease severity in psoriasis. J. Dermatol. Sci. 90, 135-143.
< , C. T. H., Kambe, N., Yamazaki, F., Ueda-Hayakawa, I., Kishimoto, I., Okamoto, H. (https://doi.org/10.1016/j.jdermsci.2018.01.005>
26. 2008) The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102-116.
< , L. P., Bradfield, C. A. (https://doi.org/10.1021/tx7001965>
27. 2013) The roles of aryl hydrocarbon receptor in immune responses. Int. Immunol. 25, 335-343.
< , N. T., Hanieh, H., Nakahama, T., Kishimoto, T. (https://doi.org/10.1093/intimm/dxt011>
28. 2016) Serum visfatin, fetuin-A, and pentraxin 3 levels in patients with psoriasis and their relation to disease severity. J. Clin. Lab. Anal. 30, 284-289.
< , G., Baki, A. M., Yorulmaz, E., Doğru-Abbasoğlu, S., Vural, P. (https://doi.org/10.1002/jcla.21850>
29. 2007) Immunopathogenesis of psoriasis. Exp. Dermatol. 16, 779-798.
< , R., Philipp, S., Höflich, C., Kreutzer, S., Wallace, E., Asadullah, K., Volk, H. D., Sterry, W., Wolk, K. (https://doi.org/10.1111/j.1600-0625.2007.00629.x>
30. 1995) Polycyclic aromatic hydrocarbon- DNA and protein adducts in coal tar treated patients and controls and their relationship to glutathione S-transferase genotype. Mutat. Res. 334, 117-124.
< , R. M., Perera, F. P., Young, T. L., Zhang, Y. J., Chiamprasert, S., Tang, D., Wang, L. W., Beachman, A., Lin, J. H., DeLeo, V. A. (https://doi.org/10.1016/0165-1161(95)90001-2>
31. 2004) Characterization of human T cells that regulate neutrophilic skin inflammation. J. Immunol. 173, 2151-2158.
< , P., Britschgi, M., Keller, M., Steiner, U. C., Steinmann, L. S., Moser, B., Pichler, W. J. (https://doi.org/10.4049/jimmunol.173.3.2151>
32. 2017) Review of the mechanism of action of coal tar in psoriasis. J. Dermatolog. Treat. 2017, 1-3.
, S., Jeon, C., Nakamura, M., Afifi, L., Yan, D., Wu, J., Liao, W., Bhutani, T. (
33. 2007) Tumour necrosis factor α (TNF-α)-converting enzyme (TACE) and soluble TNF-α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatol. Photoimmunol. Photomed. 23, 130-134.
< , A. B., Sokolowska, M., Chodynicka, B. (https://doi.org/10.1111/j.1600-0781.2007.00296.x>
34. 2015) Cytochrome P450 1b1 in polycyclic aromatic hydrocarbon (PAH)-induced skin carcinogenesis: Tumorigenicity of individual PAHs and coal-tar extract, DNA adduction and expression of select genes in the Cyp1b1 knockout mouse. Toxicol. Appl. Pharmacol. 287, 149-160.
< , L. K., Bunde, K. L., Harper, T. A. Jr, McQuistan, T. J., Löhr, C. V., Bramer, L.M., Waters, K. M., Tilton, S. C., Krueger, S. K., Williams, D. E., Baird, W. M. (https://doi.org/10.1016/j.taap.2015.05.019>
35. 2016) Genome editing of the CYP1A1 locus in iPSCs as a platform to Map AhR expression throughout human development. Stem Cells Int. 2016, 2574152.
, B. W., Stanford, E. A., Sherr, D. H., Murphy, G. J. (
36. 2014) The aryl hydrocarbon receptor: multitasking in the immune system. Annu. Rev. Immunol. 32, 403-432.
< , B., Di Meglio, P., Gialitakis, M., Duarte, J. H. (https://doi.org/10.1146/annurev-immunol-032713-120245>